Bavarian Biotech Report 2011/2012 (7MB) - Bio M

ITM Isotopen Technologien München AGPHARMA & CHEMICAL INDUSTRYKeywords: Drug Development, Drug Delivery, New Materials, Devices,Automation, Chip / Array Technology, Cardiovascular DiseasesSetting Standards with New Generation Therapies! The ITM Group providesa new generation of highly effective radioisotope therapies and integratedapplication systems to those oncological and endovascular patients who arecurrently very difficult or impossible to treat with conventional methods:ITM-Rhenium-SCT © : Skin cancer patients with large and difficult to treatlesions ITM-Rhenium-PTA © : Patients with progressed peripheral endovasculardisease, and cardiovascular patients with recurring in-stent restenosisITM-PRRT: Peptide Receptor Radioisotope Therapies: Oncological patientswith metastatic disease.Contact:Dr. Richard HenkelmannLichtenbergstr. 1D-85748 GarchingPhone: +49 (0) 8651 7678-0Fax: +49 (0) 8651 7678-20E-Mail: info@itm.agInternet: www.itm.agITM RP-München GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Cardiovascular Diseases, Small Molecules, Peptide/Protein,Devices, Drug Delivery, Clinical Diagnostics, Drug DevelopmentITM RP-München GmbH - Radiopharmazie München –is responsible forthe development of the portfolio and pipeline of radiopharmaceutical productsin oncology/personalized medicine.RPMs main focus are the so called Targeted or Peptide ReceptorRadioisotope Therapies, which have already proven their medical effectivenessand commercial viability in the treatment of various metastatic tumors.In this context an innovative peptide with a multistage targeting and internalizationmechanism has been licensed and has been brought into pre-clinicaldevelopment by RPM. First promising results in a wide variety ofvascularized tumors and metastatic melanoma could be obtained.Contact:Dr. Günter SchumacherLichtenbergstr. 1D-85748 GarchingPhone: +49 (0) 89 2891-3905Fax: +49 (0) 89 6283-6811E-Mail: info@radiopharmacy-munich.comInternet: www.radiopharmacy-munich.comKantarHealth GmbH – Clinical ResearchCROKeywords: Logistics, Clinical Research, Pharmacovigiliance, Oncology, MedicalWriting, Monitoring, AnalysisKantarHealth GmbH Clinical Research conducts phase I-IV clinical trials aswell as NIS world-wide. Our operations span local agencies in over seventycountries in Europe. KantarHealth GmbH combines more than 25 years ofCRO expertise in drug research with the development of innovative webbasedapplications in project and data management (InTrial and InDrums).Our services include: protocol and CRF design, eCRF solutions, feasibilityand site selection, investigators training, handling and completion of legaland ethical requirements, monitoring and site management, projectmanagement, implementation of risk management programs, data management,medical coding, quality assurance, statistical planning and analysis,medical writing.Contact:Siegfried FreytagLandsberger Str. 284D-80687 MünchenPhone: +49 (0) 89 5600-1421Fax: +49 (0) 89 5600-1590E-Mail: siegfried.freytag@kantarhealth.comInternet: www.kantarhealth.com79